MILAN--(BUSINESS WIRE)--
Newron Pharmaceuticals S.p.A. (“Newron”), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain, today announces that Ravi Anand, M.D., Newron’s Chief Medical Officer, will make an oral presentation entitled “Evenamide, a Putative Antipsychotic, Targets Abnormal Electrical Activity and Glutamatergic Abnormalities to Improve Psychotic Symptoms in Patients With Schizophrenia: Results From a Phase II, Placebo-Controlled Trial” at the 16th International Congress on Schizophrenia Research, ICOSR, taking place on March 24-28, 2017 at the Manchester Grand Hyatt in San Diego, California, USA.
The abstract will be presented on Saturday, March 25, 3:45-4:00 pm PT, as part of the “Clinical Trials” oral session in Seaport Ballroom F.
Evenamide (NW-3509) is a new generation antipsychotic that acts through pathways not targeted by current treatments or other putative antipsychotics. It is associated with a functional blockade of voltage-gated sodium channels that inhibits glutamate release by reducing the firing rate of hyper-excited neurons and may normalize aberrant cortical and hippocampal activity.
The double-blind, 28-day, placebo-controlled, Phase 2 study evaluated safety, tolerability, and preliminary evidence of efficacy of Evenamide as an add-on to a stable dose of risperidone or aripiprazole in 89 schizophrenia outpatients. Patients received placebo or Evenamide (15-25mg bid). The dose escalation from 15 to 20 to 25 mg bid was done weekly in an inpatient setting, based on tolerability. The study concludes that the combination of Evenamide as an add-on to marketed antipsychotics in patients showing return of symptoms would combine reduction of aberrant electrical activity and normalization of glutamate release with blockade of 5HT2/D2 receptors, thus producing a novel therapeutic option.
About Newron Pharmaceuticals
Newron (SIX: NWRN) is a
biopharmaceutical company focused on the development of novel therapies
for patients with diseases of the central nervous system (CNS) and pain.
The Company is headquartered in Bresso near Milan, Italy, with a
subsidiary in Morristown, NJ, USA. Xadago® (safinamide) has received
marketing authorization for the treatment of Parkinson’s disease in the
European Union and Switzerland and is commercialized by Newron’s partner
Zambon. US WorldMeds holds the commercialization rights in the USA.
Meiji Seika has the rights to develop and commercialize the compound in
Japan and other key Asian territories. In addition to Xadago® for
Parkinson’s disease, Newron has a strong pipeline of promising
treatments for rare disease patients at various stages of clinical
development, including sarizotan for patients with Rett syndrome and
ralfinamide for patients with specific rare pain indications. Newron is
also developing Evenamide as the potential first add-on therapy for the
treatment of patients with positive symptoms of schizophrenia. www.newron.com.
Important Notices
This document contains forward-looking
statements, including (without limitation) about (1) Newron’s ability to
develop and expand its business, successfully complete development of
its current product candidates and current and future collaborations for
the development and commercialisation of its product candidates and
reduce costs (including staff costs), (2) the market for drugs to treat
CNS diseases and pain conditions, (3) Newron’s anticipated future
revenues, capital expenditures and financial resources, and (4)
assumptions underlying any such statements. In some cases these
statements and assumptions can be identified by the fact that they use
words such as “ will”, anticipate”, “ estimate”, “ expect”, “ project”,
“intend”, “ plan”, “believe”, “ target”, and other words and terms of
similar meaning. All statements, other than historical facts, contained
herein regarding Newron's strategy, goals, plans, future financial
position, projected revenues and costs and prospects are forward-looking
statements.
By their very nature, such statements and assumptions involve inherent risks and uncertainties, both general and specific, and risks exist that predictions, forecasts, projections and other outcomes described, assumed or implied therein will not be achieved. Future events and actual results could differ materially from those set out in, contemplated by or underlying the forward-looking statements due to a number of important factors. These factors include (without limitation) (1) uncertainties in the discovery, development or marketing of products, including without limitation negative results of clinical trials or research projects or unexpected side effects, (2) delay or inability in obtaining regulatory approvals or bringing products to market, (3) future market acceptance of products, (4) loss of or inability to obtain adequate protection for intellectual property rights, (5) inability to raise additional funds, (6) success of existing and entry into future collaborations and licensing agreements, (7) litigation, (8) loss of key executive or other employees, (9) adverse publicity and news coverage, and (10) competition, regulatory, legislative and judicial developments or changes in market and/or overall economic conditions.
Newron may not actually achieve the plans, intentions or expectations disclosed in forward-looking statements and assumptions underlying any such statements may prove wrong. Investors should therefore not place undue reliance on them. There can be no assurance that actual results of Newron's research programmes, development activities, commercialisation plans, collaborations and operations will not differ materially from the expectations set out in such forward-looking statements or underlying assumptions.
Newron does not undertake any obligation to publicly up-date or revise forward looking statements except as may be required by applicable regulations of the SIX Swiss Exchange where the shares of Newron are listed. This document does not contain or constitute an offer or invitation to purchase or subscribe for any securities of Newron and no part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170315006157/en/
